Raras
Buscar doenças, sintomas, genes...
Doença da junção neuromuscular
ORPHA:98491DOENÇA RARA

Condições caracterizadas por transmissão prejudicada de impulsos na junção neuromuscular. Isto pode resultar de distúrbios que afetam a função do receptor, a função da membrana pré ou pós-sináptica ou a atividade da acetilcolinesterase. A maioria das doenças nesta categoria está associada a doenças autoimunes, tóxicas ou hereditárias.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Condições caracterizadas por transmissão prejudicada de impulsos na junção neuromuscular. Isto pode resultar de distúrbios que afetam a função do receptor, a função da membrana pré ou pós-sináptica ou a atividade da acetilcolinesterase. A maioria das doenças nesta categoria está associada a doenças autoimunes, tóxicas ou hereditárias.

Pesquisas ativas
1 ensaio
348 total registrados no ClinicalTrials.gov
Publicações científicas
40 artigos
Último publicado: 2026 Feb 13
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
59 sintomas
🧠
Neurológico
17 sintomas
🫁
Pulmão
16 sintomas
🦴
Ossos e articulações
16 sintomas
😀
Face
13 sintomas
👁️
Olhos
10 sintomas

+ 82 sintomas em outras categorias

Características mais comuns

Hiporreflexia
Fraqueza do tornozelo
Insuficiência respiratória
Fraqueza fatigável dos músculos do pescoço
Hipertrofia ventricular direita
Resposta desfavorável da fraqueza muscular a inibidores da acetilcolinesterase
229sintomas
Sem dados (229)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 229 características clínicas mais associadas, ordenadas por frequência.

HiporreflexiaHyporeflexia
Fraqueza do tornozeloAnkle weakness
Insuficiência respiratóriaRespiratory failure
Fraqueza fatigável dos músculos do pescoçoFatigable weakness of neck muscles
Hipertrofia ventricular direitaRight ventricular hypertrophy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico40PubMed
Últimos 10 anos25publicações
Pico20215 papers
Linha do tempo
2026Hoje · 2026🧪 1993Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

27 genes identificados com associação a esta condição.

ALG2Programmed cell death protein 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium sensor that plays a key role in processes such as endoplasmic reticulum (ER)-Golgi vesicular transport, endosomal biogenesis or membrane repair. Acts as an adapter that bridges unrelated proteins or stabilizes weak protein-protein complexes in response to calcium: calcium-binding triggers exposure of apolar surface, promoting interaction with different sets of proteins thanks to 3 different hydrophobic pockets, leading to translocation to membranes (PubMed:20691033, PubMed:25667979). Inv

LOCALIZAÇÃO

Endoplasmic reticulum membraneCytoplasmic vesicle, COPII-coated vesicle membraneCytoplasmNucleusEndosome

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 14ALG2-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:23159UniProt:O75340
AK9Adenylate kinase 9Candidate gene tested inTolerante
FUNÇÃO

Broad-specificity nucleoside phosphate kinase involved in cellular nucleotide homeostasis by catalyzing nucleoside-phosphate interconversions. Similar to other adenylate kinases, preferentially catalyzes the phosphorylation of the nucleoside monophosphate AMP with ATP as phosphate donor to produce ADP. In vitro, can also catalyze the phosphorylation of CMP, dAMP and dCMP and use GTP as an alternate phosphate donor. Moreover, exhibits a diphosphate kinase activity, producing ATP, CTP, GTP, UTP, T

LOCALIZAÇÃO

CytoplasmNucleusCell projection, cilium, flagellum

VIAS BIOLÓGICAS (1)
Interconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Spermatogenic failure 89

An autosomal recessive male infertility disorder due to severely reduced progressive motility of sperm.

OUTRAS DOENÇAS (2)
spermatogenic failure 89postsynaptic congenital myasthenic syndrome
HGNC:33814UniProt:Q5TCS8
LAMB2Laminin subunit gamma-1Candidate gene tested inTolerante
FUNÇÃO

Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. As a subunit of laminin-1 (also known as laminin-111 or EHS laminin), it is involved in the stimulation of agrin-induced receptor clustering through a MuSK-independent pathway

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
352.4 TPM
Ovário
317.6 TPM
Artéria tibial
293.9 TPM
Cervix Ectocervix
272.0 TPM
Cervix Endocervix
268.1 TPM
OUTRAS DOENÇAS (3)
LAMB2-related infantile-onset nephrotic syndromePierson syndromecongenital myasthenic syndrome 5
HGNC:6487UniProt:P11047
SCN4ASodium channel protein type 4 subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Pore-forming subunit of Nav1.4, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisation
MECANISMO DE DOENÇA

Paramyotonia congenita

An autosomal dominant channelopathy characterized by myotonia, increased by exposure to cold, intermittent flaccid paresis, not necessarily dependent on cold or myotonia, lability of serum potassium, non-progressive nature and lack of atrophy or hypertrophy of muscles. In some patients, myotonia is not increased by cold exposure (paramyotonia without cold paralysis). Patients may have a combination phenotype of PMC and HYPP.

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
80.7 TPM
Adipose Visceral Omentum
29.9 TPM
Mama
21.0 TPM
Tecido adiposo
18.1 TPM
Tireoide
10.4 TPM
OUTRAS DOENÇAS (12)
potassium-aggravated myotoniacongenital myopathy 22A, classiccongenital myopathy 22B, severe fetalhyperkalemic periodic paralysis
HGNC:10591UniProt:P35499
RAPSN43 kDa receptor-associated protein of the synapseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Postsynaptic protein required for clustering of nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction. It may link the receptor to the underlying postsynaptic cytoskeleton, possibly by direct association with actin or spectrin

LOCALIZAÇÃO

Cell membranePostsynaptic cell membraneCytoplasm, cytoskeleton

MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS11 is an autosomal recessive disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current.

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
43.8 TPM
Nervo tibial
4.2 TPM
Glândula adrenal
2.0 TPM
Coração - Ventrículo esquerdo
1.3 TPM
Cólon sigmoide
1.3 TPM
OUTRAS DOENÇAS (5)
fetal akinesia deformation sequence 2congenital myasthenic syndrome 11postsynaptic congenital myasthenic syndromelethal multiple pterygium syndrome
HGNC:9863UniProt:Q13702
LRP4Low-density lipoprotein receptor-related protein 4Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Mediates SOST-dependent inhibition of bone formation. Functions as a specific facilitator of SOST-mediated inhibition of Wnt signaling. Plays a key role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between motor neuron and skeletal muscle. Directly binds AGRIN and recruits it to the MUSK signaling complex. Mediates the AGRIN-induced phosphorylation of MUSK, the kinase of the complex. The activation of MUSK in myotubes induces the formation of NMJ by regul

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
ECM proteoglycans
MECANISMO DE DOENÇA

Cenani-Lenz syndactyly syndrome

A congenital malformation syndrome defined as complete and complex syndactyly of the hands combined with malformations of the forearm bones and similar manifestations in the lower limbs. It is characterized by fusion and disorganization of metacarpal and phalangeal bones, radius and ulnar shortening, radioulnar synostosis, and severe syndactyly of hands and feet.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
55.9 TPM
Skin Not Sun Exposed Suprapubic
55.2 TPM
Brain Caudate basal ganglia
38.7 TPM
Córtex cerebral
32.4 TPM
Brain Putamen basal ganglia
32.3 TPM
OUTRAS DOENÇAS (5)
sclerosteosis 2Cenani-Lenz syndactyly syndromecongenital myasthenic syndrome 17postsynaptic congenital myasthenic syndrome
HGNC:6696UniProt:O75096
SNAP25Synaptosomal-associated protein 25Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells

LOCALIZAÇÃO

Cytoplasm, perinuclear regionCell membraneSynapse, synaptosomePhotoreceptor inner segment

VIAS BIOLÓGICAS (10)
Neutrophil degranulationOther interleukin signalingToxicity of botulinum toxin type A (botA)Toxicity of botulinum toxin type E (botE)Dopamine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 117

A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE117 is an autosomal dominant form characterized by global developmental delay, delayed walking or inability to walk, intellectual disability, and early-onset seizures. Variable neurological symptoms are muscular hypotonia, movement disorders (ataxia, dystonia or tremor), cerebral visual impairment, and brain volume loss.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
3165.6 TPM
Brain Frontal Cortex BA9
1829.2 TPM
Cerebelo
1587.1 TPM
Brain Anterior cingulate cortex BA24
792.6 TPM
Córtex cerebral
685.1 TPM
OUTRAS DOENÇAS (1)
congenital myasthenic syndrome 18
HGNC:11132UniProt:P60880
ALG14UDP-N-acetylglucosamine transferase subunit ALG14Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the UDP-N-acetylglucosamine transferase complex that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAc

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 15

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness.

OUTRAS DOENÇAS (4)
intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse faciesmyopathy, epilepsy, and progressive cerebral atrophycongenital myasthenic syndrome 15obsolete congenital myasthenic syndromes with glycosylation defect
HGNC:28287UniProt:Q96F25
CHATCholine O-acetyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible synthesis of acetylcholine (ACh) from acetyl CoA and choline at cholinergic synapses

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Synthesis of PCAcetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 6, presynaptic

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS6 affected individuals have myasthenic symptoms since birth or early infancy, negative tests for anti-AChR antibodies, and abrupt episodic crises with increased weakness, bulbar paralysis, and apnea precipitated by undue exertion, fever, or excitement. CMS6 inheritance is autosomal recessive.

OUTRAS DOENÇAS (1)
congenital myasthenic syndrome 6
HGNC:1912UniProt:P28329
PREPLProlyl endopeptidase-likeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine peptidase whose precise substrate specificity remains unclear (PubMed:16143824, PubMed:16385448, PubMed:28726805). Does not cleave peptides after a arginine or lysine residue (PubMed:16143824). Regulates trans-Golgi network morphology and sorting by regulating the membrane binding of the AP-1 complex (PubMed:23321636). May play a role in the regulation of synaptic vesicle exocytosis (PubMed:24610330)

LOCALIZAÇÃO

Cytoplasm, cytosolGolgi apparatus, trans-Golgi networkCytoplasm, cytoskeletonGolgi apparatusNucleus

MECANISMO DE DOENÇA

Hypotonia-cystinuria syndrome

Characterized generalized hypotonia at birth, nephrolithiasis, growth hormone deficiency, minor facial dysmorphism, failure to thrive, followed by hyperphagia and rapid weight gain in late childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
148.0 TPM
Brain Frontal Cortex BA9
133.0 TPM
Cerebelo
92.0 TPM
Brain Nucleus accumbens basal ganglia
82.8 TPM
Hipotálamo
79.1 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (5)
myasthenic syndrome, congenital, 222p21 microdeletion syndrome without cystinuriahypotonia-cystinuria syndrome2p21 microdeletion syndrome
HGNC:30228UniProt:Q4J6C6
SLC5A7High affinity choline transporter 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

High-affinity Na(+)-coupled choline transmembrane symporter (PubMed:11027560, PubMed:11068039, PubMed:12237312, PubMed:12969261, PubMed:17005849, PubMed:23132865, PubMed:23141292, PubMed:27569547). Functions as an electrogenic, voltage-dependent transporter with variable charge/choline stoichiometry (PubMed:17005849). Choline uptake and choline-induced current is also Cl(-)-dependent where Cl(-) is likely a regulatory ion rather than cotransported ion (PubMed:11068039, PubMed:12237312, PubMed:17

LOCALIZAÇÃO

Presynaptic cell membraneCell projection, axonEarly endosome membraneCytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane

VIAS BIOLÓGICAS (2)
SLC-mediated bile acid transportAcetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 7

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND7 is characterized by onset in the second decade of progressive distal muscle wasting and weakness affecting the upper and lower limbs and resulting in walking difficulties and hand grip. There is significant muscle atrophy of the hands and lower limbs. The disorder is associated with vocal cord paresis due to involvement of the tenth cranial nerve.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
3.2 TPM
Esôfago - Junção
1.8 TPM
Brain Putamen basal ganglia
1.6 TPM
Bladder
1.6 TPM
Esôfago - Muscular
1.5 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (3)
neuronopathy, distal hereditary motor, type 7Acongenital myasthenic syndrome 20distal hereditary motor neuropathy type 7
HGNC:14025UniProt:Q9GZV3
DPAGT1UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen su

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1J

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
50.3 TPM
Cervix Endocervix
43.7 TPM
Útero
39.0 TPM
Fallopian Tube
38.1 TPM
Próstata
37.8 TPM
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 13DPAGT1-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:2995UniProt:Q9H3H5
GFPT1Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Rate-limiting enzyme of the hexosamine biosynthetic pathway (HBP) that catalyzes the formation of glucosamine-6-phosphate from fructose-6-phosphate and glutamine, thereby controlling the flux of glucose into this pathway (PubMed:32019926, PubMed:35229715). Inhibited by UDP-N-acetylglucosamine (UDP-GlcNAc) through a feedback loop (PubMed:32019926, PubMed:35229715). Fine-tunes the metabolic fluctuations of UDP-GlcNAc and its impacts on hyaluronan synthesis during tissue remodeling (PubMed:26887390

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Synthesis of UDP-N-acetyl-glucosamineXBP1(S) activates chaperone genes
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 12

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS12 is characterized by onset of proximal muscle weakness in the first decade. Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles, and sparing of ocular or facial muscles. EMG classically shows a decremental response to repeated nerve stimulation, a sign of neuromuscular junction dysfunction. Affected individuals show a favorable response to acetylcholinesterase (AChE) inhibitors.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
45.2 TPM
Fibroblastos
41.9 TPM
Pituitária
39.3 TPM
Aorta
37.8 TPM
Glândula salivar
34.7 TPM
OUTRAS DOENÇAS (2)
congenital myasthenic syndrome 12obsolete congenital myasthenic syndromes with glycosylation defect
HGNC:4241UniProt:Q06210
COLQAcetylcholinesterase collagenic tail peptideDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Anchors the catalytic subunits of asymmetric AChE to the synaptic basal membrane, and is therefore involved in the down-regulation of colinergic synaptic transmission

LOCALIZAÇÃO

Synapse

MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 5

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS5 inheritance is autosomal recessive.

OUTRAS DOENÇAS (1)
congenital myasthenic syndrome 5
HGNC:2226UniProt:Q9Y215
COL13A1Collagen alpha-1(XIII) chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in cell-matrix and cell-cell adhesion interactions that are required for normal development. May participate in the linkage between muscle fiber and basement membrane. May play a role in endochondral ossification of bone and branching morphogenesis of lung. Binds heparin. At neuromuscular junctions, may play a role in acetylcholine receptor clustering (PubMed:26626625)

LOCALIZAÇÃO

Cell membranePostsynaptic cell membrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 19

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort.

OUTRAS DOENÇAS (2)
congenital myasthenic syndrome 19postsynaptic congenital myasthenic syndrome
HGNC:2190UniProt:Q5TAT6
CHRNEAcetylcholine receptor subunit epsilonDisease-causing germline mutation(s) inTolerante
FUNÇÃO

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

VIAS BIOLÓGICAS (1)
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors
OUTRAS DOENÇAS (4)
congenital myasthenic syndrome 4Acongenital myasthenic syndrome 4Ccongenital myasthenic syndrome 4Bpostsynaptic congenital myasthenic syndrome
HGNC:1966UniProt:Q04844
MYO9AUnconventional myosin-IXaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Regulates Rho by stimulating its GTPase activity in neurons. Required for the regulation of neurite branching and motor neuron axon guidance (By similarity)

LOCALIZAÇÃO

MembraneCytoplasmSynapseCell projection, growth cone

VIAS BIOLÓGICAS (3)
RHOB GTPase cycleRHOV GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 24, presynaptic

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features include easy fatigability and muscle weakness. CMS24 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
19.2 TPM
Nervo tibial
12.7 TPM
Útero
11.1 TPM
Artéria tibial
10.6 TPM
Tireoide
10.2 TPM
OUTRAS DOENÇAS (1)
myasthenic syndrome, congenital, 24, presynaptic
HGNC:7608UniProt:B2RTY4
SLC18A3Vesicular acetylcholine transporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Electrogenic antiporter that exchanges one cholinergic neurotransmitter, acetylcholine or choline, with two intravesicular protons across the membrane of synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to store neurotransmitters inside the vesicles prior to their release via exocytosis (By similarity) (PubMed:20225888, PubMed:8910293). Determines cholinergic vesicular quantal size at presynaptic nerve terminals in developing neuro-muscular

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane

VIAS BIOLÓGICAS (1)
Acetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 21, presynaptic

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS21 is an autosomal recessive, pre-synaptic form characterized by ptosis, ophthalmoplegia, fatigable weakness, apneic crises, and deterioration of symptoms in cold water. Learning difficulties and left ventricular dysfunction may be present in some patients.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Putamen basal ganglia
4.2 TPM
Brain Caudate basal ganglia
2.6 TPM
Cólon sigmoide
1.7 TPM
Pituitária
1.6 TPM
Brain Nucleus accumbens basal ganglia
1.1 TPM
OUTRAS DOENÇAS (2)
congenital myasthenic syndrome 21fetal akinesia deformation sequence 1
HGNC:10936UniProt:Q16572
DOK7Protein Dok-7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable muscle-intrinsic activator of MUSK that plays an essential role in neuromuscular synaptogenesis. Acts in aneural activation of MUSK and subsequent acetylcholine receptor (AchR) clustering in myotubes. Induces autophosphorylation of MUSK

LOCALIZAÇÃO

Cell membraneSynapse

MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 10

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS10 is an autosomal recessive, post-synaptic form characterized by a typical 'limb girdle' pattern of muscle weakness with small, simplified neuromuscular junctions but normal acetylcholine receptor and acetylcholinesterase function.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
28.4 TPM
Coração - Átrio
27.8 TPM
Cerebelo
21.0 TPM
Músculo esquelético
19.7 TPM
Cérebro - Hemisfério cerebelar
19.5 TPM
OUTRAS DOENÇAS (4)
congenital myasthenic syndrome 10fetal akinesia deformation sequence 3postsynaptic congenital myasthenic syndromefetal akinesia deformation sequence 1
HGNC:26594UniProt:Q18PE1
CHRNDAcetylcholine receptor subunit deltaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

VIAS BIOLÓGICAS (1)
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors
MECANISMO DE DOENÇA

Multiple pterygium syndrome, lethal type

Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.

OUTRAS DOENÇAS (5)
lethal multiple pterygium syndromecongenital myasthenic syndrome 3Bcongenital myasthenic syndrome 3Ccongenital myasthenic syndrome 3A
HGNC:1965UniProt:Q07001
VAMP1Vesicle-associated membrane protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the targeting and/or fusion of transport vesicles to their target membrane

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneSynapse, synaptosomeCytoplasmic vesicle membraneMitochondrion outer membrane

VIAS BIOLÓGICAS (3)
Toxicity of botulinum toxin type F (botF)Toxicity of botulinum toxin type D (botD)Toxicity of botulinum toxin type G (botG)
MECANISMO DE DOENÇA

Spastic ataxia 1, autosomal dominant

An autosomal dominant form of spastic ataxia, a progressive neurodegenerative disorder characterized by lower-limb spasticity and generalized ataxia with dysarthria, impaired ocular movements, and gait disturbance.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
106.3 TPM
Brain Spinal cord cervical c-1
80.7 TPM
Córtex cerebral
61.8 TPM
Baço
56.5 TPM
Tireoide
56.0 TPM
OUTRAS DOENÇAS (2)
myasthenic syndrome, congenital, 25, presynapticspastic ataxia 1
HGNC:12642UniProt:P23763
MUSKMuscle, skeletal receptor tyrosine-protein kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor tyrosine kinase which plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between the motor neuron and the skeletal muscle (PubMed:25537362). Recruitment of AGRIN by LRP4 to the MUSK signaling complex induces phosphorylation and activation of MUSK, the kinase of the complex. The activation of MUSK in myotubes regulates the formation of NMJs through the regulation of different processes including the specific expression of genes in s

LOCALIZAÇÃO

Postsynaptic cell membrane

VIAS BIOLÓGICAS (1)
ECM proteoglycans
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS9 is a disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Baixa expressão)
Intestino delgado
3.1 TPM
Bladder
1.9 TPM
Testículo
1.8 TPM
Músculo esquelético
1.7 TPM
Pulmão
1.5 TPM
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 9fetal akinesia deformation sequence 1postsynaptic congenital myasthenic syndrome
HGNC:7525UniProt:O15146
AGRNAgrinDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Depending on alternative splicing and post-translational modifications, it has a role in different processes, including neuromuscular junction formation and maintenance, and regulation of neurite outgrowth (By similarity). Also involved in positive regulation of cartilage formation through alpha-dystroglycan binding and up-regulation of SOX9 (PubMed:26290588) Heparan sulfate basal lamina glycoprotein that plays a central role in the formation and the maintenance of the neuromuscular junction (NM

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixSynapseCell membrane

VIAS BIOLÓGICAS (1)
Glycosaminoglycan-protein linkage region biosynthesis
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 8

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS8 is an autosomal recessive disease characterized by prominent defects of both the pre- and postsynaptic regions. Affected individuals have onset of muscle weakness in early childhood; the severity of the weakness and muscles affected is variable.

OUTRAS DOENÇAS (2)
congenital myasthenic syndrome 8postsynaptic congenital myasthenic syndrome
HGNC:329UniProt:O00468
CHRNB1Acetylcholine receptor subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 2A, slow-channel

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane.

OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 2Acongenital myasthenic syndrome 2Cpostsynaptic congenital myasthenic syndrome
HGNC:1961UniProt:P11230
SYT2Synaptotagmin-2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Exhibits calcium-dependent phospholipid and inositol polyphosphate binding properties (By similarity). May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003)

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle, chromaffin granule membraneCytoplasm

VIAS BIOLÓGICAS (3)
Toxicity of botulinum toxin type B (botB)Clathrin-mediated endocytosisCargo recognition for clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 7A, presynaptic, and distal motor neuropathy, autosomal dominant

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS7A is an autosomal dominant, presynaptic disorder resembling Lambert-Eaton myasthenic syndrome. Affected individuals have a variable degree of proximal and distal limb weakness, muscle fatigue that improves with rest, mild gait difficulties, and reduced or absent deep tendon reflexes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
71.2 TPM
Cerebelo
57.2 TPM
Brain Frontal Cortex BA9
5.0 TPM
Brain Caudate basal ganglia
3.4 TPM
Brain Nucleus accumbens basal ganglia
2.6 TPM
OUTRAS DOENÇAS (2)
myasthenic syndrome, congenital, 7B, presynaptic, autosomal recessivecongenital myasthenic syndrome 7
HGNC:11510UniProt:Q8N9I0
SLC25A1Tricarboxylate transport protein, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial electroneutral antiporter that exports citrate from the mitochondria into the cytosol in exchange for malate (PubMed:26870663, PubMed:29031613, PubMed:29238895, PubMed:39881208, PubMed:38937634). Also able to mediate the exchange of citrate for isocitrate, phosphoenolpyruvate, cis-aconitate and to a lesser extent trans-aconitate, maleate and succinate (PubMed:29031613). Substrate exchange across the membrane occurs consecutively with one substrate being transported first, then diss

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Organic anion transport by SLC5/17/25 transporters
MECANISMO DE DOENÇA

Combined D-2- and L-2-hydroxyglutaric aciduria

An autosomal recessive neurometabolic disorder characterized by neonatal-onset encephalopathy with severe muscular weakness, intractable seizures, respiratory distress, and lack of psychomotor development resulting in early death. Brain imaging shows abnormalities including enlarged ventricles, delayed myelination, and germinal layer cysts.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
147.1 TPM
Adipose Visceral Omentum
139.8 TPM
Fígado
126.2 TPM
Fibroblastos
124.7 TPM
Artéria tibial
104.4 TPM
OUTRAS DOENÇAS (2)
myasthenic syndrome, congenital, 23, presynapticD,L-2-hydroxyglutaric aciduria
HGNC:10979UniProt:P53007
CHRNA1Acetylcholine receptor subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Upon acetylcholine binding, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane Non functional acetylcholine receptor alpha subunit which is not integrated into functional acetylcholine-gated cation-selective channels

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

VIAS BIOLÓGICAS (2)
Highly calcium permeable nicotinic acetylcholine receptorsHighly calcium permeable postsynaptic nicotinic acetylcholine receptors
MECANISMO DE DOENÇA

Multiple pterygium syndrome, lethal type

Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.

OUTRAS DOENÇAS (4)
congenital myasthenic syndrome 1Alethal multiple pterygium syndromemyasthenic syndrome, congenital, 1B, fast-channelpostsynaptic congenital myasthenic syndrome
HGNC:1955UniProt:P02708

Variantes genéticas (ClinVar)

242 variantes patogênicas registradas no ClinVar.

🧬 ALG2: NM_033087.4(ALG2):c.814G>T (p.Glu272Ter) ()
🧬 ALG2: NM_033087.4(ALG2):c.216delinsTCCCC (p.Asp73fs) ()
🧬 ALG2: GRCh37/hg19 9p24.3-q34.3(chr9:203861-141020389)x3 ()
🧬 ALG2: Single allele ()
🧬 ALG2: NM_033087.4(ALG2):c.1193T>C (p.Phe398Ser) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

72 vias biológicas associadas aos genes desta condição.

Defective ALG2 causes CDG-1i Defective ALG14 causes ALG14-CMS Interconversion of nucleotide di- and triphosphates Degradation of the extracellular matrix Laminin interactions Non-integrin membrane-ECM interactions ECM proteoglycans L1CAM interactions Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MET activates PTK2 signaling Post-translational protein phosphorylation EGR2 and SOX10-mediated initiation of Schwann cell myelination Attachment of bacteria to epithelial cells Formation of the dystrophin-glycoprotein complex (DGC) Developmental Lineage of Pancreatic Ductal Cells Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Regulation of insulin secretion Other interleukin signaling Toxicity of botulinum toxin type A (botA) Toxicity of botulinum toxin type C (botC) Toxicity of botulinum toxin type E (botE) Neutrophil degranulation GABA synthesis, release, reuptake and degradation Sensory processing of sound by inner hair cells of the cochlea Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein Synthesis of PC Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) SLC-mediated bile acid transport Defective DPAGT1 causes CDG-1j, CMSTA2 XBP1(S) activates chaperone genes Defective GFPT1 causes CMSTA1 Synthesis of UDP-N-acetyl-glucosamine Collagen degradation Collagen biosynthesis and modifying enzymes Integrin cell surface interactions Collagen chain trimerization Highly sodium permeable postsynaptic acetylcholine nicotinic receptors RHOA GTPase cycle RHOB GTPase cycle RHOV GTPase cycle Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Toxicity of botulinum toxin type D (botD) Toxicity of botulinum toxin type F (botF) Toxicity of botulinum toxin type G (botG) Glycosaminoglycan-protein linkage region biosynthesis HS-GAG biosynthesis HS-GAG degradation Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective EXT2 causes exostoses 2 Defective EXT1 causes exostoses 1, TRPS2 and CHDS NCAM1 interactions Defective B3GALT6 causes EDSP2 and SEMDJL1 Attachment and Entry Retinoid metabolism and transport Respiratory syncytial virus (RSV) attachment and entry RSV-host interactions Dengue Virus-Host Interactions Dengue Virus Attachment and Entry Toxicity of botulinum toxin type B (botB) Neurexins and neuroligins Organic anion transport by SLC5/17/25 transporters Highly calcium permeable postsynaptic nicotinic acetylcholine receptors Highly calcium permeable nicotinic acetylcholine receptors

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença da junção neuromuscular

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
25 papers (10 anos)
#1

Mendelian randomization followed by single-cell RNA sequencing exploration identifies effector memory CD4+ T cells as a risk factor for myasthenia gravis.

Medicine2026 Feb 13

Este estudo identificou um tipo específico de célula imunológica, as células T CD4+ de memória efetora, como um importante fator de risco para a Miastenia Gravis de início tardio (LOMG). Essas células foram encontradas em maior proporção em pacientes com LOMG e se expandem significativamente durante as crises da doença. Essa descoberta aprofunda a compreensão da patogênese da LOMG e pode abrir caminho para o desenvolvimento de novas estratégias de tratamento mais direcionadas.

🇧🇷 traduzido
#2

Rehabilitation in Neuromuscular Diseases: Best Turkish Practice Recommendations by Multidisciplinary Experts.

Acta neurologica Belgica2026 Feb

Este estudo turco preencheu uma lacuna importante ao desenvolver recomendações de reabilitação abrangentes para doenças neuromusculares (DNMs), incluindo as da junção neuromuscular (JNM), para pacientes de todas as idades. Uma equipe multidisciplinar de especialistas utilizou o método Delphi para criar 110 diretrizes detalhadas, que cobrem desde a gestão geral até prescrições específicas de exercícios. Essas recomendações são um guia prático essencial para médicos, otimizando o cuidado e a reabilitação de pacientes com condições como as da junção neuromuscular.

🇧🇷 traduzido
#3

Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025 Aug

Este estudo demonstra que é possível prever precocemente a Miastenia Gravis (MG) refratária, uma forma mais difícil de tratar, com base na resposta ao tratamento durante o primeiro ano de diagnóstico. Pacientes que não conseguem reduzir a dose de prednisona para menos de 20mg/dia e que necessitam iniciar outros imunossupressores orais nesse período têm um risco significativamente maior de desenvolver a doença refratária. Essa identificação precoce é crucial para médicos e pacientes, pois permite considerar intervenções mais avançadas ou novas terapias de forma mais ágil, visando melhores resultados.

🇧🇷 traduzido
#4

COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a case report.

Frontiers in immunology2025

Este artigo relata um caso raro de miastenia gravis MuSK-positiva, que se manifestou exclusivamente com insuficiência respiratória grave de início tardio, desencadeada por COVID-19. Para médicos, é crucial considerar esta doença neuromuscular em casos inexplicados de falha no desmame do ventilador — mesmo sem fraqueza muscular típica ou testes iniciais negativos. O diagnóstico precoce com anticorpos MuSK e o tratamento imunomodulador rápido (como troca de plasma) são vitais para uma recuperação rápida e podem salvar vidas.

🇧🇷 traduzido
#5

SYT2-Related Disease: A Case-Based Review.

Journal of clinical neuromuscular disease2025 Dec 01

A doença ultrarrara relacionada ao gene SYT2 manifesta-se por fraqueza e atrofia muscular distal (principalmente nas pernas), deformidades nos pés e, em alguns casos, hipotonia neonatal (bebê "mole"). Este artigo revisa os aspectos clínicos e eletrofisiológicos, descrevendo um novo caso e comparando-o com outros 27, o que é crucial para médicos no diagnóstico e para pacientes na compreensão desta doença da junção neuromuscular, apesar de ser por vezes considerada uma neuropatia motora hereditária.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC5 artigos no totalmostrando 25

2026

Mendelian randomization followed by single-cell RNA sequencing exploration identifies effector memory CD4+ T cells as a risk factor for myasthenia gravis.

Medicine
2025

COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a case report.

Frontiers in immunology
2025

SYT2-Related Disease: A Case-Based Review.

Journal of clinical neuromuscular disease
2026

Rehabilitation in Neuromuscular Diseases: Best Turkish Practice Recommendations by Multidisciplinary Experts.

Acta neurologica Belgica
2025

Algorithm for jitter measurement in neuromuscular junction disease.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology
2025

Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Bilateral horizontal gaze palsy, esotropia, and diplopia secondary to anti-Hu paraneoplastic syndrome.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2024

The Effect of Apomorphine Therapy in the Coexistence of Parkinson's Disease and Myasthenia Gravis: A Case Report and Review of the Literature.

Journal of clinical practice and research
2023

Machine learning strategy for identifying altered gut microbiomes for diagnostic screening in myasthenia gravis.

Frontiers in microbiology
2023

COVID-19 vaccination-related autoimmune hepatitis-a perspective.

Frontiers in pharmacology
2022

Seronegative Ocular Myasthenia Gravis in an Older Woman With Transient Dizziness and Diplopia.

Cureus
2024

A Common CHAT Gene Mutation of Congenital Myasthenic Syndrome Found in Kadazandusun Children.

Journal of pediatric genetics
2021

Acquired myasthenia gravis with concurrent polymyositis and myocarditis secondary to a thymoma in a dog.

Open veterinary journal
2021

Myasthenia Gravis-An Analysis of Multimodal Evoked Potentials.

Brain sciences
2021

Age at sampling and sex distribution of AChRAb vs. MuSKAb myasthenia gravis in a large Greek population.

Clinical neurology and neurosurgery
2021

Dual attack: targeting the rare co-occurrence of myasthenia gravis and Graves' disease with radioactive iodine therapy.

Endocrinology, diabetes & metabolism case reports
2021

Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2019

Paraneoplastic Syndromes in Neuro-ophthalmology.

Continuum (Minneapolis, Minn.)
2020

Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study.

Acta neurologica Belgica
2019

Clinical neurophysiology of neuromuscular junction disease.

Handbook of clinical neurology
2019

Single fiber electromyography.

Handbook of clinical neurology
2018

Clinical Image: Leriche Syndrome.

Journal of acute medicine
2020

An investigation on the effects of carbamazepine and sodium valproate on neuromuscular transmission.

Acta neurologica Belgica
2017

Analysis of TNF-related apoptosis-inducing ligand and receptors and implications in thymus biology and myasthenia gravis.

Neuromuscular disorders : NMD
2016

Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.

Muscle & nerve

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença da junção neuromuscular.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença da junção neuromuscular

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Mendelian randomization followed by single-cell RNA sequencing exploration identifies effector memory CD4+ T cells as a risk factor for myasthenia gravis.
    Medicine· 2026· PMID 41686610mais citado
  2. Rehabilitation in Neuromuscular Diseases: Best Turkish Practice Recommendations by Multidisciplinary Experts.
    Acta neurologica Belgica· 2026· PMID 41175271mais citado
  3. Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology· 2025· PMID 40281192mais citado
  4. COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a case report.
    Frontiers in immunology· 2025· PMID 41476989mais citado
  5. SYT2-Related Disease: A Case-Based Review.
    Journal of clinical neuromuscular disease· 2025· PMID 41331967mais citado
  6. Algorithm for jitter measurement in neuromuscular junction disease.
    J Electromyogr Kinesiol· 2025· PMID 40706450recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98491(Orphanet)
  2. MONDO:0020124(MONDO)
  3. GARD:19473(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q7002430(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença da junção neuromuscular
Compêndio · Raras BR

Doença da junção neuromuscular

ORPHA:98491 · MONDO:0020124
Ensaios
1 ativos
MedGen
UMLS
C0751950
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades